Mitsubishi UFJ Trust & Banking Corp Sells 22,810 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mitsubishi UFJ Trust & Banking Corp trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 3.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 606,716 shares of the medical device company’s stock after selling 22,810 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.16% of DexCom worth $47,184,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Cerity Partners LLC raised its position in shares of DexCom by 190.0% during the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock worth $4,026,000 after purchasing an additional 39,344 shares during the period. Swedbank AB increased its stake in DexCom by 15.2% during the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock valued at $14,337,000 after purchasing an additional 28,289 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in DexCom by 0.6% during the third quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company’s stock worth $5,169,000 after buying an additional 490 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of DexCom by 10.6% in the third quarter. Fisher Asset Management LLC now owns 856,124 shares of the medical device company’s stock valued at $57,395,000 after buying an additional 82,250 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of DexCom during the third quarter valued at about $961,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DXCM shares. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Cfra Research raised DexCom to a “hold” rating in a research report on Friday, March 21st. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 over the last three months. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $73.55 on Wednesday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $28.74 billion, a PE ratio of 51.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm’s 50-day simple moving average is $83.13 and its two-hundred day simple moving average is $77.11.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.